Pet Monoclonal Antibodies Market Size

Pet Monoclonal Antibodies Market Size

Pet Monoclonal Antibodies Market size was valued at USD 967.3 million in 2023 and is estimated to grow at 14.2% CAGR from 2024 to 2032. The market has experienced significant expansion owing to the rising incidence of chronic diseases and increased research endeavors focused on developing new targeted therapies to address global animal healthcare needs. Conditions such as osteoarthritis, ligament injuries, and other age-related disorders are becoming more common in both companion and livestock animals.

To get key market trends

  Download Free Sample

For instance, according to the Companion Animal Health publications, osteoarthritis accounts for at least 80% of lameness and joint disease cases in companion animals. While osteoarthritis is often linked with older animals, a recent study on its prevalence and clinical signs in young dogs (aged 8 months to 4 years) revealed that 39.8% of these animals exhibited radiographic signs of osteoarthritis in at least one joint. This highlighted the growing need for effective treatment expanding the market demand. Moreover, growing awareness among pet owners for advanced and targeted therapies continues to drive the development and adoption of pet monoclonal antibodies in the coming years.
 

Pet monoclonal antibodies are specialized proteins produced in laboratories, designed to bind to specific targets in companion animals. They mimic the immune system's ability to recognize and neutralize pathogens or abnormal cells, making them potent tools for diagnosing and treating diseases. These antibodies are engineered to be highly specific, minimizing side effects and maximizing therapeutic efficacy. They are used across various companion animal healthcare applications, including treating infectious diseases, managing immune disorders, and combating cancer.